Exploring 3 High Growth Tech Stocks in the United States

Over the last 7 days, the market has dropped 2.7%, but it has risen by 21% in the last year with earnings forecasted to grow by 15% annually. In light of these conditions, identifying high-growth tech stocks that can capitalize on this upward trajectory is crucial for investors seeking robust returns.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
TG Therapeutics	28.39%	43.54%	★★★★★★
Sarepta Therapeutics	24.22%	44.94%	★★★★★★
Super Micro Computer	20.62%	27.13%	★★★★★★
Ardelyx	27.44%	65.50%	★★★★★★
G1 Therapeutics	27.57%	57.75%	★★★★★★
Invivyd	42.91%	70.39%	★★★★★★
Ascendis Pharma	39.71%	68.43%	★★★★★★
Clene	73.06%	62.58%	★★★★★★
Seagen	22.57%	71.80%	★★★★★★
ImmunoGen	26.00%	45.85%	★★★★★★

Click here to see the full list of 251 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Apellis Pharmaceuticals (NasdaqGS:APLS)

Simply Wall St Growth Rating: ★★★★★★

Overview: Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of therapeutic compounds targeting the complement system for autoimmune and inflammatory diseases, with a market cap of $4.60 billion.

Operations: Apellis Pharmaceuticals generates revenue primarily from developing and commercializing proprietary therapeutics, amounting to $628.79 million. The company focuses on inhibiting the complement system to treat autoimmune and inflammatory diseases.

Apellis Pharmaceuticals has demonstrated significant growth, with recent revenue increasing to $199.69 million in Q2 2024 from $94.97 million a year ago and net loss narrowing to $37.66 million from $122.04 million. The company's R&D expenses reflect its commitment to innovation, with substantial investment likely contributing to the positive topline results of the Phase 3 VALIANT study, which showed a 68% reduction in proteinuria for patients treated with pegcetacoplan compared to placebo. Revenue is projected to grow at an impressive rate of 23.7% annually, outpacing the broader market's expected growth of 8.6%.

• Navigate through the intricacies of Apellis Pharmaceuticals with our comprehensive health report here.

• Review our historical performance report to gain insights into Apellis Pharmaceuticals''s past performance.

Cinemark Holdings (NYSE:CNK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cinemark Holdings, Inc., along with its subsidiaries, operates in the motion picture exhibition business and has a market cap of approximately $3.33 billion.

Operations: The company generates revenue primarily from its U.S. operations ($2.24 billion) and international markets ($596.80 million).

Cinemark Holdings has shown a promising 29.1% annual earnings growth forecast, significantly outpacing the US market's 14.9%. Despite a 9% revenue growth rate, lower than the high-growth tech benchmark of 20%, Cinemark's return on equity is projected to reach an impressive 41.7% in three years. Recent financials reveal Q2 revenue at $734.2 million and net income of $45.8 million, reflecting profitability challenges but notable potential for future gains in the entertainment sector.

• Unlock comprehensive insights into our analysis of Cinemark Holdings stock in this health report.

• Assess Cinemark Holdings' past performance with our detailed historical performance reports.

Smartsheet (NYSE:SMAR)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Smartsheet Inc. offers an enterprise platform designed to help teams and organizations plan, capture, manage, automate, and report on work, with a market cap of approximately $6.55 billion.

Operations: Smartsheet Inc. generates revenue primarily from its Internet Software & Services segment, which reported $1.00 billion in revenue. The company focuses on providing a platform that facilitates various work management tasks for teams and organizations.

Smartsheet's revenue growth of 14.3% annually outpaces the US market's 8.6%, reflecting its strong position in workplace collaboration software. The company's earnings are forecast to grow by an impressive 55.5% per year, highlighting significant future potential despite current unprofitability. Recent Q2 results showed a revenue increase to $276.41 million from $235.59 million and a net income of $7.86 million, reversing last year's loss of $33.36 million, indicating improving financial health and operational efficiency. The company has invested heavily in R&D, with expenses at approximately 30% of total revenue over recent years, fostering innovation and product development crucial for maintaining competitive advantage in the tech industry. Smartsheet’s guidance for Q3 indicates expected revenues between $282 million to $285 million, suggesting continued robust growth driven by its SaaS model that ensures recurring subscription revenues from high-profile clients like TSMC and Apple.

• Click here and access our complete health analysis report to understand the dynamics of Smartsheet.

• Learn about Smartsheet's historical performance.

Taking Advantage

• Click here to access our complete index of 251 US High Growth Tech and AI Stocks.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com